Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of...
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore...
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24...
– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week...
– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.38 | 32.2493224932 | 7.38 | 10.4 | 7.23 | 1064672 | 7.95019149 | CS |
4 | 0.43 | 4.60878885316 | 9.33 | 10.44 | 6.56 | 1256916 | 8.10269393 | CS |
12 | 1.77 | 22.1526908636 | 7.99 | 10.44 | 6.56 | 1090122 | 8.03836711 | CS |
26 | -0.81 | -7.66319772942 | 10.57 | 13.09 | 6.56 | 1062249 | 8.81944546 | CS |
52 | 0.07 | 0.722394220846 | 9.69 | 13.09 | 6.56 | 1051394 | 9.34815084 | CS |
156 | -36.24 | -78.7826086957 | 46 | 58 | 6.56 | 1161495 | 19.26232424 | CS |
260 | -3.36 | -25.6097560976 | 13.12 | 141.01 | 6.56 | 1148534 | 28.45976478 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.